Ruti Aga handed six-year ban: a family member forged the prescription, turning a two-year sanction into six

The Athletics Integrity Unit (AIU) announced on Thursday that Ethiopian marathoner Ruti Aga has been banned for six years. The sanction is not the product of a single violation but of two separate findings stacked together: a two-year ban for the presence of methylprednisolone in an in-competition sample, and a four-year ban for tampering — presenting a forged medical prescription during the investigation. The ban runs from 10 September, the date her provisional suspension took effect. The AIU statement does not spell out the year of expiry, but the arithmetic is simple: a start on 10 September puts her return roughly six years later, at age 38.

What the case is

Aga's sample was collected after she won a half marathon in China in March; it was an in-competition test. Her time, her splits, the strength of the field — none of it appears in the public statement. That is the central point: this is a governance story, not a performance story. The only competitive fact available is that she won the race, which points to a World Athletics Label-tier elite field with routine testing. The question is not how fast she ran; it is what was found afterwards and what she did about it.

The two-plus-four arithmetic

The structure is standard procedure, not an exceptional sanction. Two years for presence is consistent with a Specified Substance finding where intent is not proven. Four years for tampering is the Code's default for that offence. Together they make six. The arithmetic reveals one thing clearly: the panel did not accept the no-significant-fault mitigation that would otherwise have cut the presence sanction below two years.

A technical correction: it is not a steroid

A significant technical error has run through media coverage of this case and needs correcting. Methylprednisolone was described as a 'prohibited steroid'. It is not. It is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (class S1). The distinction is not semantic. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection administered out-of-competition is entirely legal; it becomes a violation only if residues are present in an in-competition sample.

That means the whole case rested on route of administration and timing relative to the competition, not on 'steroid use'. This is precisely where a legitimate defence existed: with genuine treatment records, timing and route could have been argued. By fabricating the prescription, she closed the one legitimate path available. It is the deepest irony of the case that the substance at the centre of a six-year ban is not a proven endurance enhancer.

The forged prescription

What the AIU investigation produced is not a simple lapse but a three-stage verification failure. First, the 'doctor' who wrote the prescription was a family member with no medical registration. Second, the clinic stamped on the document did not exist. Third, asked where the document came from, the explanation was that it was produced using 'an old prescription pad from a former workplace' — and the clinic explicitly disowned that claim.

This threefold failure makes the case aggravating, not mitigating. This was not someone filling in the wrong form. It was a document deliberately manufactured and submitted as evidence. And note: the four-year tampering ban arises not from the document alone but from statements made during an investigative interview. What was said under questioning became the basis of the sanction.

A plausible injury, not a defence

Aga cited a knee injury, and technically that is entirely plausible. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. The problem is that plausibility is not a legal defence; records are. If the treatment genuinely happened and was documented, it would have been defended with real records. Forging a prescription means the real records did not exist — or at least not in a form that could be submitted.

A larger structural question follows. Marathoners run under dual pressure from performance and appearance-fee income. Resting an injury is financially expensive. Glucocorticoids are the cheapest, most available way to mask pain. And when a formal, credentialed team physician is absent from the athlete's circle, the route leads to informal networks. The forgery is downstream of an untreated governance gap, not its cause.

Career impact: 32 to 38

Aga is 32. In elite women's marathoning that is late peak or the beginning of decline. A six-year ban removes her entirely from the 2028 Olympic cycle. For a returning 38-year-old with a doping record, selection in Ethiopia's system is practically impossible — a consequence of Ethiopian domestic depth, not of any doubt about her ability.

Her competitive record should be kept separate from this case. She won the 2026 Tokyo Marathon and has three second-place finishes at World Marathon Majors. Her personal best is reported at roughly 2:18:34 from Berlin 2026 — a figure not contained in the official statement and still requiring independent confirmation. What matters legally is that the violation is anchored to a later March race; absent a finding of earlier use, the 2026 title is not automatically annulled. The AIU statement does not define the scope of disqualification.

Even so, standard practice suggests the result, prize money and ranking points from the race where the sample was collected will be voided. That is not stated in the release, but it is how the AIU normally operates.

Ethiopian depth and the governance problem

The competitive landscape is barely affected. In Ethiopian women's marathoning a 2:18 athlete is not automatically selected — that is the measure of the depth. The removal of a 32-year-old with no global championship medals does not measurably change Ethiopia's medal capacity.

The real subject is governance. In the Ethiopian and Kenyan road-racing environments, sports medicine is often informal: credentialed team physicians, recorded treatment plans and therapeutic use exemptions are scarce. An athlete with a documented knee injection either holds a TUE or observes WADA's route-specific washout period. Neither appears to have happened here — an inference drawn from the fact that a forgery was attempted instead.

China's label-race circuit: where two economies collide

The March half marathon in China is not incidental. For East African marathoners, the Chinese and Asian label-race circuit has been an attractive, low-risk income tier: decent appearance fees between Majors, few races, limited competition. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races.

A pattern is also visible across AIU road-racing cases: the first violation concerns a substance, the second concerns its explanation — a fabricated or altered document. The enforcement frontier is shifting from detection to document verification. Aga's case is not an outlier; it belongs to a recognisable cluster.

Scope for appeal

In principle an appeal lies to the Court of Arbitration for Sport, typically within about 21 days of the reasoned decision. But a forgery finding is document-based and very hard to overturn. Backdating the ban to the provisional suspension is a procedural benefit, not a reduction — it does not shorten the real period.

The wider message

Six years for a glucocorticoid is a striking outcome, particularly for a substance with no proven endurance benefit. The result will be cited from both directions: as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. The truth is that the difference was made not by the substance but by the document. With genuine medical records, the case might never have existed, or would have been a light one. The six years were earned by something that happened outside the sport: making a fake document.

What comes next

Three questions remain open: when the March race result and prize money will be formally annulled; whether the Ethiopian athletics federation issues any statement (the AIU has, the federation has not); and whether document forgery opens a route to criminal action at national level — outside AIU jurisdiction and currently unanswered. The largest question is whether this case changes the informal medical network that made it possible, or simply adds another name to a list.